ARTICLE | Market Access
FDA approves blockbuster FCRN inhibitor for a second indication, chronic inflammatory demyelinating polyneuropathy
By Stephen Hansen, Director of Biopharma Intelligence
June 21, 2024 9:35 PM UTC
Growth of argenx’s Vyvgart could get another shot in the arm after the Dutch biotech received an FDA label expansion for the FCRN inhibitor to treat CIDP.
First approved in 2021 and launched in 1Q22, Vyvgart efgartigimod and its subcutaneous formulation Vyvgart Hytrulo have been the growth engine for argenx S.E. (Euronext:ARGX; NASDAQ:ARGX), with sales for its first indication of generalized myasthenia gravis (gMG) hitting more than $1.2 billion in just its second year on the market…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652779/label-expansion-for-argenx-lifts-vyvgart-s-growth-prospects